Tiate, Blessa Rose Q.
HRN: 23-80-10 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/19/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
12/19/2023
12/26/2023
IV
500mg
Q8 X 7 Days
S/P Primary LTCS
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes